Table 1. Characteristics of included studies.

Studies	Year	Study population	Design	Age, year	Male,%	ACS,%	N	Durationof DAPT||,months	Follow-up,months	MACE# definition
COMPARE II16	2013	Patients eligible for PCI*	open-label, randomized (2∶1),controlled, non-inferiority	62.9	74.4	57.9	2707	12	12	Cardiac death, MI**, and clinically indicated TVR††
SORT OUT V17	2013	SAP†/ACS‡+ at least one >50% stenosis	open-label, randomized (1∶1),controlled, non-inferiority	65.1	74.8	48.9	2468	12	12	Cardiac death, MI, definite ST‡‡, and clinically-driven TVR
NOBORI 1 (Phase 1+2)25–26,31	2007	SAP/UA§/provocable ischemia eligible for PCI	open-label, randomized (2∶1),controlled, non-inferiority	62.9	72.4	28.0	263	6	24	Cardiac death, MI, emergent cardiac bypass surgery, and TVR
LEADERS18,27	2008	SAP or ACS eligible for PCI	Single-blinded, randomized (1∶1),controlled, non-inferiority	64.6	74.8	55.2	1707	12	48	Cardiac death, MI, and clinically-indicated TVR
NOBORI JAPAN28	2011	SAP/UA/provocable ischemia eligible for PCI	open-label, randomized (3∶2),controlled	67.3	71.8	14.4	335	3	9	Cardiac death, MI, and TLR§§
Separham, et al30	2012	Patients eligible for PCI	open-label, randomized (1∶1),controlled	NA	NA	NA	200	NA	12	Cardiac death, MI, and TVR
NEXT29	2013	Patients eligible for PCI	Assessor-blinded, randomized(1∶1), controlled	69.2	77	16.5	3235	3	12	Cardiac death, MI, and TLR

^*PCI: percutaneous coronary intervention;

^†SAP: stable angina pectoris;

^‡ACS: acute coronary syndrome;

§UA: unstable angina;

^||DAPT: dual antiplatelet therapy (protocol mandated); ^#MACE: major adverse cardiac events;

^**MI: myocardial infarction;

^††TVR: target vessel revascularization;

^‡‡ST: stent thrombosis;

^§§TLR: target lesion revascularization.